In the published article, there was an error in Figure 2 as published. The unit of IVIG dosage was displayed as “mg”. The corrected Figure 2 and its caption Comparison of (A) IVIG dosage and (B) IVIG duration between the survival group and the death group. **P <0.01. appear below.
Figure 2
In the published article, there was an error in Figure 4 as published. The unit of IVIG dosage was displayed as “mg”. The corrected Figure 4 and its caption Kaplan–Meier curves estimating 28-day mortality in SFTS patients based on (A) IVIG dosage and (B) IVIG duration. appear below.
Figure 4
In the published article, there was an error in Table 1 as published. The unit of IVIG dosage was displayed as “mg”. The corrected Table 1 and its caption Baseline clinical characteristics and laboratory parameters of patients in the survival and death groups. appear below.
Table 1
| Variable | Survival (n = 36) | Death (n = 26) | P-value |
|---|---|---|---|
| Demographics | |||
| Age, years | 67 (54-73) | 71 (58-76) | 0.199 |
| Male, n (%) | 18 (50.0%) | 11 (42.3%) | 0.549 |
| Chronic comorbidities, n (%) | |||
| Hypertension | 11 (30.6%) | 10 (38.5%) | 0.516 |
| Diabetes mellitus | 3 (8.3%) | 2 (7.7%) | 1.000 |
| Malignancy | 1 (2.78%) | 0 (0%) | 1.000 |
| CAD | 1 (2.78%) | 0 (0%) | 1.000 |
| COPD | 0 (0%) | 1 (3.85%) | 0.419 |
| Clinical manifestations, n (%) | |||
| Nausea | 12 (33.3%) | 7 (26.9%) | 0.589 |
| Vomiting | 10 (27.8%) | 9 (34.6%) | 0.564 |
| Celialgia | 4 (11.1%) | 2 (7.7%) | 0.653 |
| Diarrhea | 17 (47.2%) | 10 (38.5%) | 0.492 |
| Unintelligible speech | 1 (2.8%) | 3(11.5%) | 0.300 |
| Dizziness and headache | 18 (50.0%) | 6 (23.1%) | 0.032 |
| Cough | 9 (25.0%) | 4 (15.4%) | 0.359 |
| Sputum | 7 (19.4%) | 3 (11.5%) | 0.627 |
| Chest tightness | 3 (8.3%) | 3 (11.5%) | 0.689 |
| Rash | 6 (16.7%) | 1 (3.8%) | 0.222 |
| Lymphadenopathy | 13 (36.1%) | 7 (26.9%) | 0.445 |
| Bleeding spots on the skin | 7 (19.4%) | 9 (34.6%) | 0.178 |
| Laboratory parameters | |||
| WBC count, median (IQR), ×109/L | 2.5 (1.8-4.6) | 2.7 (1.7-3.7) | 0.898 |
| ANC count, median (IQR), ×109/L | 1.7 (1.0-2.9) | 2.1 (1.2-2.8) | 0.668 |
| ALC count, median (IQR), ×109/L | 0.7 (0.4-0.9) | 0.5 (0.3-0.6) | 0.042 |
| NLR, median (IQR) | 2.2 (1.5-6.1) | 3.3 (1.9-9.1) | 0.136 |
| RDW, median (IQR), % | 13.2 (12.8-13.5) | 13.6 (12.8-14.3) | 0.071 |
| PLT count, median (IQR), ×109/L | 44.5 (33.8-61.3) | 39.5 (29.0-58.5) | 0.480 |
| PLR, median (IQR) | 65.5 (39.3-146) | 89.6 (67.5-145.0) | 0.248 |
| PT, median (IQR), s | 12.0 (11.2-12.6) | 12.4 (11.7-13.0) | 0.123 |
| APTT, median (IQR), s | 41.4 (33.6-46.3) | 48.5 (37.6-61.1) | 0.009 |
| TT, median (IQR), s | 22.8 (21.1-27.7) | 26.9 (21.8-57.9) | 0.057 |
| D-dimer, median (IQR), mg/L | 3.8 (2.3-9.2) | 9.9 (3.4-22.6) | 0.018 |
| ALT, median (IQR), U/L | 69.6 (54.3-97.2) | 75.3 (50.5-90.5) | 0.881 |
| AST, median (IQR), U/L | 172.5 (93.4-312.9) | 222.0 (114.1-321.8) | 0.304 |
| ALB, median (IQR), g/L | 32.0 (28.7-35.7) | 31.7 (29.1-34.1) | 0.775 |
| TBIL, median (IQR), µmol/L | 11.0 (8.6-13.9) | 7.7 (5.8-11.5) | 0.066 |
| SCr, median (IQR), µmol/L | 72.5 (48.8-89.6) | 82 (67.5-123.6) | 0.090 |
| BUN, median (IQR), mmol/L | 5.2 (3.5-7.1) | 5.9 (4.8-10.6) | 0.061 |
| UA, median (IQR), µmol/L | 306 (236-347) | 342 (231-463) | 0.471 |
| IVIG usage | |||
| IVIG dosage, g | 95.0 (57.5-100.0) | 60.0 (40.0-100.0) | 0.066 |
| IVIG duration, d | 5 ± 2 | 4 ± 2 | 0.003 |
| Additional information | |||
| Time from onset to arriving in hospital, d | 7 ± 3 | 7 ± 2 | 0.317 |
| Time from onset to IVIG treatment, d | 9 ± 3 | 9 ± 3 | 0.677 |
Baseline clinical characteristics and laboratory parameters of patients in the survival and death groups.
CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; WBC, white blood cell; ANC, absolute neutrophil count; ALC, absolute lymphocyte count; NLR, neutrophil-to-lymphocyte ratio; RDW, red cell volume distribution width; PLT, platelet; PLR, platelet-to-lymphocyte ratio; PT, prothrombin time; APTT, activated partial thromboplastin time; TT, thrombin time; ALT, alanine aminotransferase; AST, aspartate aminotransferase; ALB, serum albumin; TBIL, total bilirubin; SCr, serum creatinine; BUN, blood urea nitrogen; UA, uric acid; IVIG, intravenous immunoglobulin; IQR, interquartile range.
In the published article, there was an error. The unit of IVIG dosage was displayed as “mg”.
A correction has been made to Introduction, Paragraph Number 161. This sentence previously stated:
“Ultimately, we determined that an IVIG dosage of more than or equal to 80 mg through a prolonged treatment duration of five or more days serves as a good prognosis predictor in SFTS with neurological symptoms.”
The corrected sentence appears below:
“Ultimately, we determined that an IVIG dosage of more than or equal to 80 g through a prolonged treatment duration of five or more days serves as a good prognosis predictor in SFTS with neurological symptoms.”
A correction has been made to Results, Paragraph Number 694. This sentence previously stated:
“Patients with an IVIG dosage of more than or equal to 80 mg (Figure 4A) and an IVIG duration of 5 days or more (Figure 4B) had higher survival rates.”
The corrected sentence appears below:
“Patients with an IVIG dosage of more than or equal to 80 g (Figure 4A) and an IVIG duration of 5 days or more (Figure 4B) had higher survival rates.”
A correction has been made to Discussion, Paragraph Number 884. This sentence previously stated:
“In this study, our findings suggested that higher dosages (≥80 mg) and a prolonged duration of IVIG treatment may improve the prognosis of SFTS patients.”
The corrected sentence appears below:
“In this study, our findings suggested that higher dosages (≥80 g) and a prolonged duration of IVIG treatment may improve the prognosis of SFTS patients.”
The authors apologize for the errors and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Statements
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Summary
Keywords
intravenous immunoglobulin, mortality, severe fever with thrombocytopenia syndrome, neurological complications, dosage, duration
Citation
Liu Y, Tong H, He F, Zhai Y, Wu C, Wang J and Jiang C (2024) Corrigendum: Effect of intravenous immunoglobulin therapy on the prognosis of patients with severe fever with thrombocytopenia syndrome and neurological complications. Front. Immunol. 15:1383797. doi: 10.3389/fimmu.2024.1383797
Received
08 February 2024
Accepted
25 March 2024
Published
05 April 2024
Volume
15 - 2024
Edited by
Keun Hwa Lee, Hanyang University, Republic of Korea
Reviewed by
Jeong Rae Yoo, Jeju National University, Republic of Korea
Updates
Copyright
© 2024 Liu, Tong, He, Zhai, Wu, Wang and Jiang.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Chenxiao Jiang, sharejcx@163.com; Jun Wang, wjgaogou@aliyun.com; Chao Wu, dr.wu@nju.edu.cn
†These authors have contributed equally to this work
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.